1. Home
  2. GLPG vs ARQT Comparison

GLPG vs ARQT Comparison

Compare GLPG & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLPG
  • ARQT
  • Stock Information
  • Founded
  • GLPG 1999
  • ARQT 2016
  • Country
  • GLPG Belgium
  • ARQT United States
  • Employees
  • GLPG N/A
  • ARQT N/A
  • Industry
  • GLPG Biotechnology: Pharmaceutical Preparations
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • GLPG Health Care
  • ARQT Health Care
  • Exchange
  • GLPG Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • GLPG 1.8B
  • ARQT 1.7B
  • IPO Year
  • GLPG 2005
  • ARQT 2020
  • Fundamental
  • Price
  • GLPG $29.92
  • ARQT $14.22
  • Analyst Decision
  • GLPG Sell
  • ARQT Strong Buy
  • Analyst Count
  • GLPG 4
  • ARQT 6
  • Target Price
  • GLPG $25.33
  • ARQT $18.80
  • AVG Volume (30 Days)
  • GLPG 226.8K
  • ARQT 1.9M
  • Earning Date
  • GLPG 07-23-2025
  • ARQT 08-13-2025
  • Dividend Yield
  • GLPG N/A
  • ARQT N/A
  • EPS Growth
  • GLPG N/A
  • ARQT N/A
  • EPS
  • GLPG N/A
  • ARQT N/A
  • Revenue
  • GLPG $311,493,731.00
  • ARQT $212,819,000.00
  • Revenue This Year
  • GLPG $0.78
  • ARQT $61.15
  • Revenue Next Year
  • GLPG N/A
  • ARQT $37.98
  • P/E Ratio
  • GLPG N/A
  • ARQT N/A
  • Revenue Growth
  • GLPG 18.32
  • ARQT 100.03
  • 52 Week Low
  • GLPG $22.36
  • ARQT $7.86
  • 52 Week High
  • GLPG $31.23
  • ARQT $17.75
  • Technical
  • Relative Strength Index (RSI)
  • GLPG 62.12
  • ARQT 54.56
  • Support Level
  • GLPG $28.21
  • ARQT $13.06
  • Resistance Level
  • GLPG $29.23
  • ARQT $14.31
  • Average True Range (ATR)
  • GLPG 0.53
  • ARQT 0.63
  • MACD
  • GLPG 0.09
  • ARQT 0.01
  • Stochastic Oscillator
  • GLPG 93.93
  • ARQT 71.17

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: